Scientists at Sanford Burnham Prebys Medical Discovery Institute say that a new molecular machinery-targeting drug dubbed SBI-756 demonstrated preclinical evidence of success in a mouse model for melanoma. And they add that the drug may prove particularly useful for treatment-resistant cases of skin cancer. "The unique target of SBI-756 makes it especially promising for use in combination therapy," said Ze'ev Ronai, senior author and scientific director of SBP's La Jolla campus. "A major issue limiting the effectiveness of current melanoma therapies is that tumors become resistant to treatment. Combining drugs that come at a melanoma from different angles may help overcome the problem of drug resistance." Release | Abstract